Confirmation of Change in ADS Ratio

RNS Number : 1430U

AstraZeneca PLC

27 July 2015

 



AstraZeneca PLC - Confirmation of Change in ADS ratio

AstraZeneca PLC (the "Company") today confirmed that the intended ratio change to its NYSE-listed sponsored Level 2 American Depositary Receipt ("ADR") programme announced on 26 June 2015 has now become effective. With effect from 27 July 2015, the Company's American Depositary Share ("ADS") ratio is two (2) ADSs per one (1) Ordinary Share. The former ratio was one (1) ADS per one (1) Ordinary Share. There are no changes to the underlying Ordinary Shares.

ADS holders at the close of business New York time on the record date, 22 July 2015, received a distribution of one additional ADS for every ADS held. No action was required by ADS holders to effect this change.

Contact details for Citibank, N.A., the Company's ADR depositary, can be found below.

A C N Kemp

Company Secretary

27 July 2015

CONTACT

Citibank Shareholder Services

PO Box 43077  Providence RI 02940-3077 US

Tel (toll free in the US): [phone] Tel (outside the US): [phone]

Media Enquiries

Esra Erkal-Paler	[phone] (UK/Global)
Jacob Lund	[phone] (Sweden)
Michele Meixell	+ 1 302 885 6351 (US)

Investor Enquiries

UK
Thomas Kudsk Larsen		[phone]	mob: [phone]
Eugenia Litz	Respiratory, Inflammation and Autoimmunity	[phone]	mob: [phone]
Nick Stone	Cardiovascular and Metabolic Disease	[phone]	mob: [phone]
Karl Hård	Oncology	[phone]	mob: [phone]
Craig Marks	Infection, Neuroscience and Gastrointestinal Disease	[phone]	mob: [phone]
Christer Gruvris		[phone]	mob: [phone]
US
Dial / Toll-Free		301-398-3251	866-381-7277

 

END

 

 

MSCRRMPTMBITMBA